neuroleptic malignant syndrome


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to neuroleptic malignant syndrome: tardive dyskinesia, Serotonin syndrome

neuroleptic

 [noor″o-lep´tik]
a term coined to refer to the effects on cognition and behavior of the original antipsychotic agents, which produced a state of apathy, lack of initiative, and limited range of emotion and in psychotic patients caused a reduction in confusion and agitation and normalization of psychomotor activity. The term is still used to refer to agents, such as droperidol, used to produce such effects as part of anesthesia or analgesia; however, it is outdated as a synonym for antipsychotic agents because newer agents do not necessarily have such effects.
neuroleptic malignant syndrome a rare but dramatic condition that occurs in severely ill patients being treated with high-potency antipsychotics (neuroleptics); symptoms include diaphoresis, muscle rigidity, and hyperpyrexia. It is believed to be caused by dopamine blockade in the hypothalamus.

neu·ro·lep·tic ma·lig·nant syn·drome

hyperthermia with extrapyramidal and autonomic disturbances that may result in death, following the use of neuroleptic agents.

neuroleptic malignant syndrome

Etymology: Gk, neuron, nerve, lepsis, seizure; L, malignus, bad disposition; Gk, syn, together, dromos, course
a condition characterized by hypertonicity, pallor, dyskinesia, fever, incontinence, unstable blood pressure, and pulmonary congestion. It is caused by the administration of neuroleptic drugs at normal or high doses. Reaction to these drugs is idiosyncratic.

neuroleptic malignant syndrome

Neurology A disorder seen in those receiving antipsychotics–eg, haloperidol, major tranquilizers, and other agents–eg, phenothiazines, reserpine, butyrophenone, an effect attributed to dopamine blockade in the basal ganglia and hypothalamus; NMS may also be associated with anesthesia, affecting +– 1:50,000 Pts exposed to inhalation anesthesia, most commonly in young ♂, transiently weakened by exhaustion, dehydration Clinical Fever ≥ 41ºC, extrapyramidal Sx–eg, rigidity, involuntary movements, facial dyskinesia, skeletal muscle hypertonicity, loss of consciousness, autonomic lability–pallor, sweating, tachycardia, arrhythmia, transient HTN which, if severe, may cause renal failure Mortality 20-30%, often between days 3-30, usually from renal failure Treatment Bromocriptine or dantrolene may shorten clinical disease.

neu·ro·lep·tic ma·lig·nant syn·drome

(nūr'ō-lep'tik mă-lig'nănt sin'drōm)
Hyperthermia with extrapyramidal and autonomic disturbances that may result in death, following the use of neuroleptic agents.

neuroleptic malignant syndrome

A rare and sometimes fatal disorder related to the use of any NEUROLEPTIC drug in any dosage. It features high fever, sweating, severe rigidity of muscles, wide swings of blood pressure, incontinence, confusion and coma.
References in periodicals archive ?
Declining frequency of neuroleptic malignant syndrome in a hospital population.
Neuroleptic malignant syndrome with prolonged catatonia in a dopa-responsive dystonia patient.
Neuroleptic malignant syndrome presenting without fever: case report and review of the literature.
The study also showed that inpatient mortality because of neuroleptic malignant syndrome (NMS) has significantly dropped since it was first described in 1960.
Another possible cause of CK elevation, which is neuroleptic malignant syndrome (NMS), was eliminated since the patient had no other symptoms such as fever or leukocytosis.
In recent years, CK elevations related to use of atypical antipsychotics have been reported in several case studies in the absence of neuroleptic malignant syndrome.
Zuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girl.
Neuroleptic malignant syndrome associated with atypical antipsychotics in paediatric patients: a review of published cases.
A broad range of disorders is covered, including acute dystonic reactions, neuroleptic malignant syndrome, startle syndromes, and tic emergencies.
Abstract: Neuroleptic malignant syndrome (NMS) is a potentially lethal condition that has been described in patients with idiopathic Parkinson's disease (PD) after long-term dopaminergic medications are suddenly stopped or moderately decreased.
By the second day of his hospitalization, the patient's condition met the diagnostic criteria for neuroleptic malignant syndrome (NMS) secondary to dopamine withdrawal.